Bruce M. Katz, MD, discusses the results of two phase 3 clinical trials on daxibotulinumtoxinA for injection, the development of a onabotulinumtoxinA biosimilar, and the current state and future of cosmetic dermatology practice.
Dr Katz is clinical professor of dermatology at the Icahn School of Medicine at Mount Sinai, past director of the Cosmetic Surgery & Laser Clinic at Mount Sinai Hospital, and director of the Juva Skin & Laser Center, all in New York City, NY. He is recognized as a leading innovator of advanced laser technology and multiple skin rejuvenation techniques. His research has been published extensively in leading medical and scientific journals, and Dr Katz lectures frequently at medical symposia domestically and abroad.
Read more about SAKURA OLS, which tested the safety and efficacy of daxibotulinumtoxinA for injection for long-term use, in our coverage of the American Academy of Dermatology Virtual Meeting Experience 2020!